BioMarin acquires Amicus Therapeutics

BioMarin agreed to acquire Amicus Therapeutics. Reported deal value: $4.7B. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: Princeton, New Jersey, United States.

This page summarizes publicly available information about the transaction as of 2026-01-26. Figures and status may change as filings and press coverage update.

BioMarin also announced that, in connection with the pending acquisition of Amicus Therapeutics , Inc. , it launched the syndication of a new $2 billion senior secured term loan 'B' facility , which Term Loan B Facility is in addition to a $800 million senior secured term loan 'A' facility , and a $600 million senior secured revolving credit facility into which BioMarin expects to enter in connection with the Acquisition